Provided by Tiger Fintech (Singapore) Pte. Ltd.

Viatris Inc.

10.17
+0.07000.69%
Post-market: 10.02-0.1516-1.49%19:55 EDT
Volume:5.51M
Turnover:55.91M
Market Cap:11.86B
PE:-3.48
High:10.20
Open:10.09
Low:10.07
Close:10.10
52wk High:13.55
52wk Low:6.85
Shares:1.17B
Float Shares:1.16B
Volume Ratio:0.74
T/O Rate:0.48%
Dividend:0.48
Dividend Rate:4.72%
EPS(TTM):-2.9198
EPS(LYR):-0.5315
ROE:-19.77%
ROA:2.30%
PB:0.76
PE(LYR):-19.14

Loading ...

Idorsia Ltd. Publishes Investor Presentation on Advancing Towards Profitability and Strategic Priorities

Reuters
·
Jul 30

Idorsia Ltd. Reports Significant Revenue Growth to CHF 130 Million and Reduced Non-GAAP Net Loss in H1 2025; EPS Improves to CHF (0.13)

Reuters
·
Jul 30

Viatris Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
Jul 29

The Trader: GM Is Loading Up on Its Own Shares. Investors Should Follow Suit. -- Barron's

Dow Jones
·
Jul 26

Viatris Inc. Stock Rises Tuesday, Outperforms Market

Dow Jones
·
Jul 23

Viatris Inc. Stock Falls 4.2%, Underperforms Market

Dow Jones
·
Jul 19

US FDA advisers vote against Otsuka's PTSD combination treatment

Reuters
·
Jul 19

BUZZ-U.S. STOCKS ON THE MOVE-Independent Bank, Invesco

Reuters
·
Jul 19

BUZZ-U.S. STOCKS ON THE MOVE-Eos Energy, Norfolk Southern, Coinbase

Reuters
·
Jul 19

Sector Update: Health Care Stocks Edge Higher Pre-Bell Friday

MT Newswires Live
·
Jul 18

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target -- Barrons.com

Dow Jones
·
Jul 18

Viatris Fails to Meet Primary Endpoint of Phase 3 Study for Blepharitis Treatment

MT Newswires Live
·
Jul 18

Viatris eye therapy fails to meet late-stage trial goal

Reuters
·
Jul 18

Viatris Inc. Announces Positive Results from Phase 3 Trials of MR-142 and MR-141, and Provides Update on MR-139 Study for Blepharitis

Reuters
·
Jul 18

Viatris Inc. Stock Rises Wednesday, Outperforms Market

Dow Jones
·
Jul 17

FDA staff raises efficacy concerns for Otsuka's PTSD combination drug

Reuters
·
Jul 16

Viatris Inc. Stock Falls Tuesday, Underperforms Market

Dow Jones
·
Jul 16

GSK Viiv Extends Cabotegravir Licensing Deal to Include HIV Treatment

MT Newswires Live
·
Jul 14

Viatris Inc. Stock Falls Friday, Underperforms Market

Dow Jones
·
Jul 12

BRIEF-FDA Discontinues Mylan Pharmaceuticals' Potassium Chloride Tablet

Reuters
·
Jul 09